Daiichi Sankyo
Eric Olszewski currently serves as the Head of Global External Stakeholder Engagement in Global Compliance and Risk Management at Daiichi Sankyo US since January 2012, where responsibilities include transforming global compliance processes and collaborating with various departments to mitigate risks. Prior roles at Daiichi Sankyo include Director of Compliance Policy & Training and Associate Director of Medical Communications, where Eric focused on policy development, compliance training, and strategic medical communication for key products like Effient. Previously, Eric held consulting and leadership positions at Merck and Euro RSCG, and extensive marketing roles at sanofi-aventis, leading efforts in diabetes and thrombosis product commercialization. Eric began a career in pharmaceutical sales with Marion Merrell Dow, building market share in Western New York. Educational qualifications include an MBA in Marketing and Finance from the University of Rochester - Simon Business School and a B.S. in Marketing from Canisius University.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.